8-K: Bausch + Lomb Reports Q1 2025 Results; Updates Full-Year Guidance Due to enVista Recall

Bausch + Lomb announced its first-quarter 2025 financial results, including revenue growth of 3% (5% on a constant currency basis) and an update to its full-year guidance to reflect the impact of the enVista IOL voluntary recall.

Summary

• Bausch + Lomb reported first-quarter 2025 revenue of $1.137 billion, a 3% increase compared to $1.099 billion in the first quarter of 2024.
• On a constant currency basis, revenue increased by approximately 5%.
• The company experienced a GAAP net loss attributable to Bausch + Lomb Corporation of $212 million, compared to a net loss of $167 million in the same period last year.
• Adjusted EBITDA excluding Acquired IPR&D was $126 million, down from $180 million in the first quarter of 2024.
• The company updated its full-year 2025 revenue guidance to $5.000B $5.100B and adjusted EBITDA excluding Acquired IPR&D to $850M $900M, reflecting the impact of the enVista IOL voluntary recall and foreign exchange headwinds.
• The voluntary recall of enVista IOLs is estimated to have a one-time impact of ~$55M on revenue and ~$65M on adjusted EBITDA.
• The company announced the return to market of enVista intraocular lenses (IOLs) following the voluntary recall.
• The company is focused on advancing its pipeline, with forthcoming clinical studies for multiple novel products.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased, the net loss widened, and guidance was lowered due to the recall. The company is taking steps to address the issues and is focused on long-term growth.

Positives

• Revenue increased by 3% year-over-year, and 5% on a constant currency basis.
• Vision Care and Surgical segments showed revenue growth of 3% and 9% respectively.
• The company is seeing revenue growth in daily and FRP contact lens portfolios, led by Daily SiHy.
• MIEBO is showing momentum with sequential quarter-over-quarter revenue growth, and phase 4 data demonstrates rapid relief from dry eye symptoms.
• The company announced the return to market of enVista intraocular lenses (IOLs) following the voluntary recall.

Negatives

• The company experienced a GAAP net loss attributable to Bausch + Lomb Corporation of $212 million, compared to a net loss of $167 million in the same period last year.
• Adjusted EBITDA excluding Acquired IPR&D decreased to $126 million from $180 million in the first quarter of 2024.
• The Pharmaceuticals segment revenue remained flat compared to the first quarter of 2024.
• The company updated its full-year 2025 revenue guidance to $5.000B $5.100B and adjusted EBITDA excluding Acquired IPR&D to $850M $900M, reflecting the impact of the enVista IOL voluntary recall and foreign exchange headwinds.

Risks

• The voluntary recall of enVista IOLs has a significant financial impact.
• Foreign exchange headwinds are negatively impacting revenue and adjusted EBITDA.
• The U.S. Generics business is experiencing a decline.
• Gross-to-net headwinds, primarily attributable to XIIDRA, are impacting the Pharmaceuticals segment.
• Adverse economic conditions and macroeconomic factors, including heightened inflation and interest rates, fluctuations in exchange rates, imposition of and adverse changes to tariff, duties and other trade protection measures, slower growth or a potential recession, which could adversely impact our revenue, expenses and resulting margins.

Future Outlook

Bausch + Lomb updated its full-year 2025 guidance, anticipating revenue between $5.000B and $5.100B and adjusted EBITDA excluding Acquired IPR&D between $850M and $900M. This guidance reflects the estimated one-time impact of the enVista recall and foreign exchange headwinds.

Management Comments

• Our core business is performing well, and we remain focused on positioning the company for long-term, profitable growth, said Brent Saunders, chairman and CEO, Bausch + Lomb.
• Were making meaningful progress in our journey to significantly enhance the standard of care in eye health, which motivates us every day.

Industry Context

Bausch + Lomb operates in the global eye health market, which includes vision care, surgical, and pharmaceutical products. The company's performance is influenced by factors such as competition, technological advancements, and regulatory changes. The recall of the enVista IOLs highlights the importance of product quality and safety in the medical device industry.

Comparison to Industry Standards

• Comparing Bausch + Lomb's revenue growth of 3% (5% constant currency) to competitors like Alcon (NYSE: ALC) and Johnson & Johnson Vision (JNJ), which also operate in similar segments, provides a benchmark for performance.
• Alcon, for example, has reported similar growth rates in certain quarters, while J&J Vision's performance varies depending on product cycles and market conditions.
• The adjusted EBITDA margin of Bausch + Lomb, excluding Acquired IPR&D, can be compared to the EBITDA margins of these competitors to assess profitability and operational efficiency.
• The impact of the enVista IOL recall can be compared to similar product recalls in the medical device industry to understand the potential financial and reputational consequences.

Stakeholder Impact

• Shareholders will be impacted by the lower earnings and revised guidance.
• Employees may be affected by cost-cutting measures or restructuring.
• Customers may experience temporary disruptions in the supply of certain products.
• Suppliers may be affected by changes in demand or pricing.
• Creditors will monitor the company's financial performance and ability to meet its obligations.

Next Steps

• The company will continue to monitor the impact of the enVista IOL recall and work to return to full market supply.
• The company will focus on advancing its pipeline and launching new products.
• The company will manage expenses and improve profitability.
• The company will execute its consumer growth strategy.

Key Dates

Keywords

Bausch + Lomb, Financial Results, Q1 2025, Revenue, EBITDA, Guidance, enVista IOL, Recall, Vision Care, Surgical, Pharmaceuticals, MIEBO, Contact Lenses